Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like Italian Medicines Agency Nails Drugmaker for Major Deficiencies May 29, 2019 CUPID Disappoints Sanofi, Regeneron for Chronic Spontaneous Urticaria Drug February 18, 2022 Teva and MedinCell Receive Complete Response Letter for Schizophrenia Drug April 20, 2022